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Pharmacologic suppression of
experimental abdominal aortic aneurysms:
A comparison of doxycycline and four
chemically modified tetracyclines
John A. Curci, MD, Drazen Petrinec, MD, Shixiong Liao, MD, Lorne M.
Golub, DMD, MSc, and Robert W. Thompson, MD, St Louis, Mo, and Stony
Brook, NY
Background: Matrix metalloproteinases (MMPs) likely contribute to the degradation of
medial elastin in abdominal aortic aneurysms (AAAs), and tetracycline antibiotics exhib-
it MMP-inhibiting properties. The purpose of this study was to compare the effects of
doxycycline and several non–antibiotic chemically modified tetracyclines (CMTs) in a rat
model of elastase-induced AAA.
Methods: Fifty-two male Wistar rats underwent intraluminal perfusion of the abdominal
aorta with porcine pancreatic elastase. The rats then were treated for 7 days with sub-
cutaneous injections of saline solution, different doses of doxycycline, or 1 of 4 differ-
ent CMTs. The aortic diameters were measured with microcalipers, and the fixed tissues
were examined by means of light microscopy. Gelatin zymography was used to assess the
MMP activity in the aortic tissue extracts.
Results: The mean aortic diameter in the control group increased by 126% ± 14% on day
7 (from 1.57 ± 0.04 mm to 3.54 ± 0.27 mm; P < .05), and 5 of 6 animals (83%) had
AAAs. Doxycycline appeared to inhibit aortic dilatation in a dose-dependent manner,
and AAAs did not develop in any animals. Half-maximal effects were observed at a dose
of approximately 6 mg/kg/day, and maximal effects were noted at greater than 30
mg/kg/day. No AAAs were observed in the animals that were treated with CMTs at 15
mg/kg/day. Each of the following CMTs exhibited an efficacy that was similar to that
of doxycycline (percent inhibition of aortic dilatation vs control; all P < .05): CMT-3
(47.6%), CMT-4 (38.9%), CMT-7 (47.6%), CMT-8 (54.0%), and doxycycline (51.6%).
Tissues from saline solution–treated controls exhibited a transmural inflammatory
response and marked destruction of the medial elastic lamellae. Tetracycline derivatives
limited the disruption of medial elastin without appearing to alter either the inflamma-
tory response or the rat aortic wall production of metallogelatinases.
Conclusion: Tetracycline derivatives suppress the development of AAAs after elastase-
induced aortic injury in the rat. The aneurysm-suppressing effects of doxycycline appear
to be dose-dependent and distinct from its antibiotic activities, and they coincide with
the structural preservation of medial elastin fibers. Further studies are needed to explore
the potential of MMP-inhibiting tetracyclines as a novel pharmacologic strategy for the
suppression of aortic aneurysms. (J Vasc Surg 1998;28:1082-93.)
From the Department of Surgery (Drs Curci, Petrinec, Liao, and
Thompson) and the Department of Cell Biology and Physiology
(Dr Thompson), Washington University School of Medicine,
and the Department of Oral Biology and Pathology (Dr Golub),
School of Dental Medicine, State University of New York at
Stony Brook.
Supported by a faculty fellowship from the American College of
Surgeons, a Research Grant-in-Aid from the American Heart
Association, Missouri Affiliate, and PHS Grant R29 HL56701.
Part of this work was presented in abstract form at a New York
Academy of Sciences Conference on “The abdominal aortic
aneurysm: genetics, pathophysiology, and molecular biology,”
Mar 7–9, 1996, New York, NY.
Reprint requests: Robert W. Thompson, MD, Section of Vascular
Surgery, Washington University School of Medicine, 9901
Wohl Hospital, 4960 Children’s Place, St Louis, MO 63110.
Copyright © 1998 by The Society for Vascular Surgery and
International Society for Cardiovascular Surgery, North
American Chapter.
0741-5214/98/$5.00 + 0 24/1/93673
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 6 Curci et al 1083
The development, expansion, and rupture of
abdominal aortic aneurysms (AAAs) all are closely
associated with the process of connective tissue
destruction.1 Although aneurysm rupture is thought
to arise primarily through the disruption of adventitial
collagen, the biophysical properties of the aneurysmal
aorta are largely attributable to the loss of medial and
adventitial elastin.2-5 Elastic fibers, as a result of their
hydrophobic nature and extensive intermolecular
cross-linking, are extremely resistant to physicochemi-
cal deterioration or nonspecific enzymatic degrada-
tion.6 Elastin is thereby one of the most biologically
stable components of the extracellular matrix, and it
also undergoes little metabolic turnover in adult tis-
sues.7 These considerations have led to the view that
the destruction of elastic fibers observed in AAAs 
must result from the increased local activity of elastin-
specific enzymes.1,8-10
A number of elastolytic proteinases have been
described in human AAA tissues. These enzymes
include both serine proteases8,9 and metallopro-
teinases,10-13 with members of the matrix metallo-
proteinase (MMP) family appearing to play a domi-
nant role.14-21 92-kD gelatinase (MMP-9) is the
most prominent elastase secreted by AAA tissues in
organ culture, and MMP-9 messenger RNA and
protein both are localized to aneurysm-infiltrating
macrophages in vivo.19 72-kD gelatinase (MMP-2)
also is found in human AAA, where it is expressed by
vascular smooth muscle cells, fibroblasts, and
endothelium, often in areas adjacent to mononu-
clear phagocytes.16,18 Recent evidence indicates that
additional elastin-degrading MMPs, particularly
matrilysin (MMP-7) and macrophage metalloelas-
tase (MMP-12), also are expressed in human
aneurysm tissues.20,21
Several laboratories have used the elastase-
induced rodent model of AAA, which originally was
described by Anidjar et al,22 to investigate the role of
endogenous proteinases in aneurysmal degenera-
tion.22-29 In this system, only mild aortic dilatation
is observed immediately after intraluminal perfusion
with porcine pancreatic elastase and there is initially
little evidence of elastin degradation detectable by
means of light microscopy. A rapid and significant
increase in aortic diameter begins to occur about 2
to 3 days later, with aneurysms typically developing
within 7 to 10 days. The delayed onset of aortic
dilatation in this model is temporally and spatially
associated with aortic wall infiltration by mononu-
clear phagocytes, increased local expression of elas-
tolytic metalloproteinases, and pronounced destruc-
tion of the medial elastic lamellae.22-29
We have examined the hypothesis that an
increase in rat aortic wall MMPs is responsible for
the development of elastase-induced AAA.26-29 On
the basis of the recognition that tetracycline antibi-
otics exert direct MMP-inhibiting activities,30 one of
these studies tested the effects of doxycycline in this
model.27 We confirmed that doxycycline effectively
inhibits MMPs derived from the elastase-injured rat
aortic wall in vitro and discovered that it suppresses
the development of elastase-induced AAA in vivo.27
Because the MMP-inhibiting properties of doxycy-
cline are shared by a novel class of nonantibiotic
tetracycline derivatives (chemically modified tetracy-
clines, or CMTs),31 we predicted that CMTs also
might prevent elastase-induced aneurysmal degener-
ation in the rat.28 In this report, we present evidence
that the aneurysm-suppressing effects of doxycycline
appear to occur in a dose-dependent fashion, that
these effects can be observed at clinically achievable
dose schedules, and that the mechanism of action
does not require antibiotic activity. These findings
support the view that novel pharmacologic strategies
with tetracycline derivatives might have potential in
the management of small asymptomatic aortic
aneurysms.
MATERIALS AND METHODS
Elastase perfusion model of abdominal aortic
aneurysm. A total of 52 male Wistar rats that
weighed from 350 to 400 g underwent elastase per-
fusion of the abdominal aorta according to a proto-
col approved by the Washington University Animal
Studies Committee, as previously described.27 After
intraperitoneal injection of 6% sodium pentobarbital
solution (0.1 mL per 100 g body weight), a laparot-
omy was performed under sterile conditions. The
abdominal aorta was exposed from the level of the
left renal vein to the aortic bifurcation by means of a
binocular surgical microscope (Leica, Deerfield, Ill).
The inferior mesenteric artery and all lumbar artery
branches arising from the infrarenal aorta were ligat-
ed, and the preperfusion aortic diameter (AD) was
measured to within 0.05 mm with microcalipers. A
PE-10 polyethylene catheter (Baxter, McGraw Park,
Ill) was introduced through a femoral arteriotomy,
and its tip was positioned within the distal abdomi-
nal aorta. The infrarenal aorta then was clamped
above the level of the catheter tip. At the level of the
distal aorta, a silk ligature was secured around the
aortic bifurcation to encompass the catheter without
occluding it. This provided an isolated segment of
distal abdominal aorta approximately 15 mm in
length. The aorta then was perfused gently for a 2-
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hour period with 2 mL of saline solution that con-
tained 50 units of type I porcine pancreatic elastase
(#E-1250, Sigma Chemical Co, St Louis, Mo).
Elastase perfusion was performed at a constant phys-
iologic pressure (100 mm Hg) with a calibrated
syringe pump (Sage Instruments, Boston, Mass).
After elastase perfusion, the aortic clamp and silk lig-
ature were removed to restore normal aortic blood
flow. The polyethylene catheter was withdrawn, the
femoral artery was ligated, and the postperfusion
AD was measured. The animals were allowed to
recover from anesthesia and thereafter were main-
tained in individual cages with free access to food
and water. The abdominal aorta was reexposed
through a laparotomy with pentobarbital anesthesia
on day 7. The final AD was measured under physio-
logic conditions immediately before death from
intravenous pentobarbital overdose. 
Pharmacologic treatment. Approximately 8
hours after recovery from the elastase perfusion, all
the animals began treatment with twice-daily subcuta-
neous injections of either saline solution, different
doses of doxycycline, or 1 of 4 different CMTs.
Doxycycline (6-deoxy, 5-hydroxy tetracycline) was
purchased from Sigma Chemical Co and administered
in doses of 0 (saline solution alone), 7.5, 15, 30, or
60 mg/kg/day (n = 6 rats in each group). Four
nonantibiotic CMTs that are known to exhibit MMP-
inhibiting properties were generously provided by
Collagenex, Inc (Wayne, Pa). Each CMT was dis-
solved initially in dimethylsulfoxide before mixing
with saline solution (final concentration of dimethyl-
sulfoxide, <1%), and all CMTs were administered at
15 mg/kg/day (5 or 6 rats in each group). The fol-
lowing chemical structures of the tetracyclines used in
this study are shown in Fig 1: doxycycline (6-deoxy,
5-hydroxy tetracycline), CMT-3 (6-demethyl, 6-
deoxy, 4-dedimethylamino tetracycline), CMT-4 (7-
chloro, 4-dedimethylamino tetracycline), CMT-7
(12-deoxy, 4-dedimethylamino tetracycline), and
CMT-8 (6-deoxy, 5-hydroxy, 4-dedimethylamino
tetracycline).
Aortic diameter measurements and statistical
analysis. Individual measurements of preperfusion,
postperfusion and final AD were recorded for each
animal. The increase in AD was determined in mm
( D AD mm = final AD – preperfusion AD) and
expressed as a percentage change (D AD%), with each
animal serving as its own control. Aortic aneurysms
were defined as a D AD% greater than 100 (ie, twice-
normal) to be compatible with the clinical defini-
tions of aneurysm disease. For each treatment
group, the mean ± standard error of the mean of
preperfusion AD, postperfusion AD, final AD, D AD
mm, and D AD% were determined. The percent inhi-
bition of aortic dilatation was determined by com-
paring the mean D AD% for each treatment group
with that of the control group treated with saline
solution alone. Statistical comparisons between the
groups were made with either analysis of variance
with the Student-Newman-Keuls test for multiple
comparisons or with the 2-tailed Student t test for
paired comparisons.32
Morphologic assessment. After death, 3 ani-
mals in each group underwent systemic perfusion-
fixation with 10% neutral buffered formalin. Fixative
was perfused at 120 mm Hg for 10 minutes with the
left ventricle for inflow and the right atrium for
efflux. The abdominal aorta was excised, immersed
in 10% neutral buffered formalin at 4°C overnight,
and processed for routine embedding in paraffin.
Aortic tissue sections were cut at 7-m m in thickness
and attached to glass slides, and serial sections were
stained with either hematoxylin and eosin or
Verhoeff–van Gieson stain for elastin. The slides
were examined with a BX60 light microscope
(Olympus America, Inc, Melville, NY), and repre-
sentative cross-sectional areas of the aortic wall were
imaged with a PM-30 automatic photomicrograph-
ic system (Olympus).
Substrate zymography. Aortic tissues were
excised from 2 animals in each group, and total 
protein extracts were prepared as previously
described.27 Briefly, frozen aortic tissue samples
were pulverized with liquid nitrogen and extracted
in ice-cold 50 mmol/L Tris-HCl buffer (pH 7.5),
that contained 1.0 mol/L NaCl, 2.0 mol/L urea,
0.1% ethylenediamine tetra-acetate, and 0.1%
(wt/vol) Brij-35 (Sigma). After centrifugation at
10,000g for 1 hour at 4°C, the supernatant was dia-
lyzed overnight against 50 mmol/L Tris HCl (pH
8.0), 1.0 mol/L NaCl, and 20 mmol/L CaCl2, with
a 12,000 to 14,000 molecular weight cut-off mem-
brane. The total protein concentration of each sam-
ple was determined with an assay kit purchased from
Bio-Rad (Hercules, Calif). Protein-normalized sam-
ples were mixed with nonreducing sample buffer
that contained 0.1% sodium dodecylsulfate and then
electrophoretically resolved through 10% polyacryl-
amide gels copolymerized with 1 mg/mL gelatin
substrate (Sigma Chemical Co). The gels were
washed free of sodium dodecylsulfate with 2.5%
Triton X-100 (Bio-Rad) and incubated overnight at
37°C in a substrate buffer that contained 50
mmol/L Tris-HCl (pH 8.5), 5 mmol/L CaCl2, and
0.02% NaN3. After staining with 0.1% Coomassie
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Blue R-250 (Sigma) in 40% methanol/10% acetic
acid, gelatinase activities were observed as clear
bands against a dark background of intact substrate.
The relative molecular weight of each proteolytic
band was estimated by comparison with the migra-
tion positions of known molecular-weight standards
(Bio-Rad, Richmond, Calif) and authentic human
92-kD and 72-kD gelatinases. The relative concen-
tration of each band that corresponded to 92-kD
and 72-kD gelatinase was quantitated with a flatbed
scanner and a Phoretix 1D Plus imaging software
(version 3.01) obtained from Phoretix International
(Newcastle upon Tyne, United Kingdom).
RESULTS
Doxycycline inhibits elastase-induced aneurys-
mal dilatation. As shown in Table I, all the animals
exhibited a moderate increase in AD immediately
after elastase perfusion, but the extent of postelastase
aortic dilatation did not reach aneurysmal propor-
tions in any individual animal. The animals in the
saline solution–treated control group (n = 6) exhib-
ited an increase in mean AD from 1.57 ± 0.04 mm
before elastase perfusion to 3.54 ± 0.27 mm on day
7, with an overall increase of 126 ± 16 percent (P <
.05). AAA developed in 5 of 6 control animals
(83%). In contrast, no aneurysms were observed in
Fig 1. Chemical structures of tetracycline derivatives. A, Chemical groups responsible for dif-
ferent biologic activities of tetracycline derivatives are outlined on structure of tetracycline
nucleus. The 4-dimethylamino group is required for antibiotic activity (single arrow), and the
11-oxy and 12-hydroxy groups are responsible for direct metalloproteinase inhibition (split
arrow). B, Doxycycline (6-deoxy, 5-hydroxy tetracycline). C, CMT-3 (6-dimethyl, 6-deoxy, 4-
dedimethylamino tetracycline. D, CMT-4 (7-chloro, 4-dedimethylamino tetracycline). E,
CMT-7 (12-deoxy, 4-dedimethylamino tetracycline). F, CMT-8 (6-deoxy, 5-hydroxy, 4-dedi-
methylamino tetracycline). Modifications in each of the nonantibiotic CMTs predominantly
influence their biologic availability and pharmacokinetic properties, without diminishing
antimetalloproteinase potency.
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the 24 animals that were treated with doxycycline.
The animals in the doxycycline-treated groups also
consistently exhibited less aortic dilatation than did
the control group, with an overall mean increase in
AD of only 60% ± 4% (P < .05). Thus, the extent of
aortic dilatation in the entire doxycycline-treated
group was suppressed by 52.4% as compared with the
saline solution–treated control group. 
Fig 2 shows that the aneurysm-inhibiting effects
of doxycycline were also dose-dependent, with max-
imal inhibition of aortic dilatation (60% of control)
at doses greater than 30 mg/kg/day, 51% inhibition
at 15 mg/kg/day, and 38% inhibition at 7.5
mg/kg/day. With paired analysis, there were signif-
icant differences between the doses of 0 and 7.5
mg/kg/day doxycycline, and between 7.5 and 15
mg/kg/day doxycycline (P < .05, Student t test).
Half-maximal inhibition of aortic dilatation (30% of
control) was calculated to occur at a dose of approx-
imately 5.9 mg/kg/day. Whereas the recommended
dose of doxycycline in clinical practice is 50 to 100
mg orally twice a day (1.4 to 2.8 mg/kg/day for 
a person who weighs 70 kg), in the treatment of
some conditions, doxycycline is administered at
doses as high as 200 mg orally twice a day (5.7
mg/kg/day).33 Subcutaneous administration of
doxycycline was therefore projected to suppress the
development of elastase-induced AAA by approxi-
mately 30% within a clinically achievable dose range
of 6 mg/kg/day, but this still represents a dose
about 2-fold to 4-fold greater than that typically
used in the treatment of bacterial infection. 
Tetracycline inhibition of aneurysmal dilata-
tion is independent of antibiotic activity. As
shown in Table II, elastase-induced aortic dilatation
also was inhibited by each of the 4 nonantibiotic
CMTs tested. When considered together, the mean
increase in AD for all 22 CMT-treated animals was
only 66% ± 5% compared with 126% ± 16% for saline
solution–treated controls (P < .05). Thus, the over-
all mean inhibition of aortic dilatation was 47.6%
and, like doxycycline-treated rats, no aneurysms
were observed in the animals treated with CMTs.
Each CMT was administered at a single dose of 15
mg/kg/day. Because this dose is within the ascend-
ing portion of the dose-response curve for doxycy-
cline, it should have been optimal for detecting any
significant differences between compounds. By
paired comparison of each individual compound
with saline solution alone, the mean inhibition of
aortic dilatation was 47.6% of control for CMT-3,
38.9% of control for CMT-4, 47.6% of control for
CMT-7, and 54.0% of control for CMT-8 (all P <
.05). Compared with doxycycline administered at
the same dose (15 mg/kg/day), the relative
aneurysm-suppressing efficacy of each CMT was
92% for CMT-3, 75% for CMT-4, 92% for CMT-7,
and 105% for CMT-8. None of these differences
were significantly different from doxycycline at 15
mg/kg/day (Fig 3). These data show that the
Table I. Aortic diameter measurements in rats treated with doxycycline
AD before AD after
elastase elastase
perfusion perfusion AD at day 7 D AD D AD
Group n (mm) (mm) (mm) (mm) (%)
Saline solution 
alone 6 1.57 ± 0.04 2.06 ± 0.02 3.54 ± 0.27* 1.98 ± 0.26 126 ± 16
Doxycycline 
(7.5 mg/kg/day) 6 1.53 ± 0.03 2.26 ± 0.03 2.72 ± 0.07*† 1.19 ± 0.06† 78 ± 3
Doxycycline 
(15 mg/kg/day) 6 1.57 ± 0.02 2.14 ± 0.03 2.53 ± 0.14*† 0.96 ± 0.12† 61 ± 7
Doxycycline 
(30 mg/kg/day) 6 1.52 ± 0.03 2.18 ± 0.04 2.28 ± 0.10*† 0.76 ± 0.11† 51 ± 8
Doxycycline 
(60 mg/kg/day) 6 1.58 ± 0.09 2.06 ± 0.07 2.34 ± 0.05*† 0.77 ± 0.08† 50 ± 7
Doxycycline-All‡ 24 1.55 ± 0.02 2.16 ± 0.03 2.46 ± 0.06*† 0.92 ± 0.06† 60 ± 4
All animals underwent elastase perfusion of the abdominal aorta as described in the text, followed by treatment with different doses of
doxycycline (mg/kg/day, subcutaneously). Aortic diameter (AD) was measured at the intervals indicated. The increase in AD (D AD)
for individual animals was determined as the difference between final AD measured at sacrifice (day 7) and the AD measured before elas-
tase perfusion, recorded in both mm and as percent change. All data represent the mean ± standard error of the mean.
AD, Aortic diameter.
*P < .01, aortic diameter at day 7 versus aortic diameter before elastase perfusion, with Student t test.
†P < .05 versus saline solution, with analysis of variance and Student-Newman-Keuls multiple comparisons test.
‡Doxycycline-All indicates aggregate data for all doxycycline-treated animals.
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aneurysm-suppressing effects of tetracyclines are not
dependent on antibiotic activity but that they coin-
cide with the known capacity of these compounds to
directly inhibit MMP activities.34-36
Morphologic changes associated with tetracy-
cline treatment. Histologic examination of aortic
tissues obtained 7 days after the elastase perfusion
revealed the destruction of the medial elastic lamellae
and an intense, transmural, mononuclear inflamma-
tory response in the control group treated with saline
solution alone (Fig 4, A and B). Treatment with
tetracycline derivatives did not appear to prevent or
substantially influence the aortic wall inflammatory
response; specifically, macrophage infiltration of the
elastase-injured aorta was present regardless of treat-
ment with tetracyclines at any dose. Nonetheless, the
structure of the medial elastic lamellae was well-
preserved in the animals treated with either doxycy-
cline or CMTs, in a manner that appeared to corre-
spond with the dose administered (Fig 4, C and F).
Treatment with tetracycline derivatives also appeared
to promote the development of dense collagenous
fibrosis in the adventitia, another factor that may help
to suppress aneurysmal dilatation. These findings are
compatible with the view that tetracyclines act by
inhibiting MMPs involved in aortic elastin and colla-
gen degradation, and furthermore, they suggest that
MMP activity is required for the development of
aneurysmal degeneration in this model.
Effect of tetracycline derivatives on rat aortic
wall production of MMP activities. As shown in
Fig 5, substrate zymography consistently revealed
the presence of 72-kD gelatinase in extracts of nor-
mal rat aorta, but 92-kD gelatinase was unde-
tectable. Neither elastase perfusion or subsequent
treatment with tetracyclines had a significant effect
on the amount of 72-kD gelatinase activity present.
In contrast, elastase-perfused animals treated with
saline solution exhibited a marked increase in the
amount of extractable 92-kD gelatinase activity.
Aortic tissue extracts from animals treated with
doxycycline also contained similarly elevated
amounts of 92-kD gelatinase up to a dose of 30
mg/kg/day, but the amount of extractable 92-kD
gelatinase was diminished only at the highest dose
tested (60 mg/kg/day). There was also no signifi-
cant decrease in the amount of 92-kD gelatinase in
rats treated with CMTs at 15 mg/kg/day. Because
tissue homogenates extracted with 2 mol/L of urea
and detergent can be expected to contain most cel-
lular and matrix-bound enzymes and because gelatin
zymography detects latent and activated forms of
MMPs (and those complexed with tissue inhibitors
of metalloproteinases), the amount of activity
Fig 2. Dose-dependent inhibition of aortic dilatation with
doxycycline. Rats were treated with subcutaneous doxycy-
cline at doses indicated for 7 days after elastase-induced
aortic injury. Final aortic diameter was determined for 6
animals in each treatment group. For each dose of doxy-
cycline, mean reduction in aortic diameter is expressed as
percentage (mean ± standard error of the mean) of that
observed in controls treated with saline solution alone.
Maximal inhibitory effects were observed at doses greater
than 30 mg/kg/day, and half-maximal inhibition was cal-
culated at a dose of approximately 5.9 mg/kg/day.
*P < .05 versus saline-solution controls, analysis of variance
and Student-Newman-Keuls multiple comparisons test.
†P < .05 versus previous dose, Student t test.
Fig 3. Relative inhibition of aortic dilatation with doxycy-
cline and chemically modified tetracyclines (CMTs). Rats
were treated with subcutaneous injection with 15
mg/kg/day of doxycycline or with 1 of 4 CMTs for 7 days
after elastase-induced aortic injury. For each treatment
group, mean reduction in final aortic diameter is expressed
as percentage (mean ± standard error of the mean) of that
observed in controls treated with saline solution alone.
There were no significant differences between the
inhibitory effects of doxycycline versus any of the 4 CMTs
(P > .05, Student t test).
Solid bar, Doxycycline; hatched bars, individual CMTs;
open bar, pooled data for all 4 CMTs. 
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detected by zymography likely reflects the overall
amount of gelatinase present in the tissue. Thus,
diminshed tissue production of metallogelatinases is
not necessarily observed after treatment with tetra-
cyclines, despite the effective suppression of
aneurysmal dilatation and the apparent reduction in
elastin degradation induced by these compounds.
This is consistent with other data that indicate that
the principal inhibitory effect of tetracyclines occurs
at the level of extracellular enzyme activity.34-36
DISCUSSION
AAAs represent a chronic degenerative disease
characterized by progressive aortic dilatation, tortu-
osity, and eventual rupture. Pathologic changes that
are typical of human AAA include the destruction of
medial and adventitial elastic fibers and a decrease in
aortic wall elastin concentration.1-5 These changes
are accompanied by a chronic transmural inflamma-
tory response with features of autoimmuni-
ty,16,19,37,38 dense medial neovascularization,39 and
a decrease in medial smooth muscle cell density.40
Previous investigations have emphasized the poten-
tial role played by MMPs as direct mediators of aor-
tic wall connective tissue destruction in this disease,
which leads to speculation that MMP inhibition
might provide a novel therapeutic strategy for
AAA.1,20
The elastase-perfused rat aorta has been an infor-
mative model of AAA because the sequence of
events reproduces many changes observed in human
disease.22-29 Thus, transient elastase perfusion
appears to induce a cascade of events in the other-
wise normal rat aorta, including transmural aortic
wall inflammation enriched in mononuclear phago-
cytes, increased local production of elastolytic
MMPs, and progressive elastin degradation. Each of
these events exhibits a temporal and spatial correla-
tion with the development of aneurysmal dilatation,
and they parallel the recognized histologic features
of human AAA. Moreover, at least 2 of the elas-
tolytic MMPs that are present in human AAA tissues
also are actively expressed in the elastase-injured rat
aorta (ie, MMP-2 and MMP-9).27,29 This model
therefore has been useful to examine the role that
MMPs might play in the early process of aneurysmal
degeneration.
We have reported previously that the develop-
ment of elastase-induced AAA is inhibited by treat-
ment with doxycycline, a synthetic tetracycline
derivative with antibiotic effects.27 This result was
consistent with the known metalloproteinase-
inhibiting activity of tetracyclines,30,31,34-36 coupled
with the following 3 hypotheses regarding the
mechanisms responsible for aneurysmal degenera-
tion: (1) the initial elastase-induced injury promotes
the recruitment of mononuclear phagocytes into the
damaged aortic wall; (2) aortic elastin degradation is
mediated by chronic inflammtory cells through their
elaboration of elastolytic MMPs; and (3) pro-
nounced elastin degradation is required for the
development of aneurysmal dilatation. The
aneurysm-suppressing effects of doxycycline also
were associated with the morphologic preservation
of aortic medial elastin and a reduction in aortic wall
MMP-9 activity, without a detectable influence on
aortic wall inflammatory cell infiltration.27 This
study extends these investigations by showing that
Table II. Aortic diameter measurements in rats treated with chemically modified tetracyclines
AD after
AD before elastase
elastase perfusion perfusion AD at day 7 D AD
Group n (mm) (mm) (mm) (mm) D AD (%)
Saline solution 6 1.57 ± 0.04 2.06 ± 0.02 3.54 ± 0.27* 1.98 ± 0.26 126 ± 16
CMT-3 5 1.52 ± 0.02 2.28 ± 0.03 2.53 ± 0.16*† 1.01 ± 0.15† 66 ± 9
CMT-4 5 1.54 ± 0.04 2.32 ± 0.03 2.73 ± 0.23*† 1.19 ± 0.21† 77 ± 13
CMT-7 6 1.56 ± 0.04 2.34 ± 0.03 2.58 ± 0.04*† 1.02 ± 0.06† 66 ± 5
CMT-8 6 1.56 ± 0.04 2.30 ± 0.03 2.45 ± 0.13*† 0.89 ± 0.14† 58 ± 10
All CMTs‡ 22 1.55 ± 0.02 2.31 ± 0.02 2.57 ± 0.07*† 1.02 ± 0.07† 66 ± 5
All animals underwent elastase perfusion of the abdominal aorta as described in the text, followed by treatment with saline solution or
1 of 4 different chemically modified tetracyclines (15 mg/kg/day, subcutaneously). Aortic diameter (AD) was measured at the intervals
indicated. The increase in AD (D AD) for individual animals was determined as the difference between the final AD measured at sacrifice
(day 7) and the AD measured before elastase perfusion, recorded in both mm and as percent change. All data shown represent the mean
± standard error of the mean.
AD, aortic diameter; CMT, chemically modified tetracycline.
*P < .01, aortic diameter at day 7 versus aortic diameter before elastase perfusion, with Student t test.
†P < .05 versus saline solution, with Student t test.
‡All CMTs indicates aggregate data for all chemically modified tetracycline–treated animals.
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the aneurysm-inhibiting effects of doxycycline are
dose-dependent, that effective inhibition of aortic
dilatation can occur at clinically achievable doses of
doxycycline, and that equivalent results can be
obtained with CMTs, a novel class of MMP-inhibit-
ing tetracycline derivatives devoid of antibiotic activ-
ity. These findings lend further support to the
hypothesis that the development of elastase-induced
rodent aneurysms requires the action of endogenous
MMPs expressed as a consequence of the aortic wall
response to injury and, moreover, that these MMPs
are likely responsible for aortic elastin and collagen
degradation. 
There are several features that distinguish the rat
model from human aneurysm disease. For example,
it is dependent on the induction of aortic wall injury
with porcine pancreatic elastase, a potent serine pro-
tease that does not play any known or suspected role
in the natural development of AAA. With the con-
ditions used in this study and others, only mild aor-
tic dilatation is induced immediately after elastase
perfusion, there is no significant damage to aortic
Fig 4. Structural changes in elastase-perfused rat aorta induced by treatment with tetracycline
derivatives. Rat tissue specimens were obtained 7 days after aortic perfusion and stained with
Verhoeff–van Gieson stain. This stain displays elastic fibers in black and collagen fibers in red.
A, Perfusion with saline solution, no treatment. B, Perfusion with porcine pancreatic elastase
(PPE), treatment with saline solution alone. C, Perfusion with PPE, treatment with 7.5
mg/kg/day doxycycline. D, Perfusion with PPE, treatment with 15 mg/kg/day doxycycline.
E, Perfusion with PPE, treatment with 30 mg/kg/day doxycycline. F, Perfusion with PPE,
treatment with 15 mg/kg/day CMT-7. Original magnification, 60· .
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medial elastin detectable by means of light
microscopy, and residual elastase activity is unde-
tectable within the aortic wall.22-29 Nonetheless,
aortic perfusion with either saline solution or heat-
inactivated elastase does not induce the delayed
development of AAA.26,27 These observations
exclude the mechanical effects of perfusion alone or
the introduction of a foreign (porcine) protein as
mechanisms by which elastase perfusion initiates
aneurysmal degeneration. Thus, even though tran-
sient elastase perfusion can be expected to produce
severe tissue damage within the aortic wall microen-
vironment, the exact role of elastase in the produc-
tion of experimental aneurysms remains unknown.
The results of this study have potentially impor-
tant implications for the use of MMP inhibitors to
limit the growth of small asymptomatic AAA.1
Tetracyclines are attractive candidates for the inves-
tigation of this therapeutic strategy on the basis of
their efficacy as MMP inhibitors, relatively low cost,
established safety, and clinical familiarity in the treat-
ment of other chronic conditions.33 There is also
evidence that tetracyclines can selectively accumulate
in atherosclerotic plaques, a factor that may be rele-
vant to the treatment of human aneurysm disease.41
As illustrated in Fig 1, the structure-activity rela-
tionships responsible for the antimicrobial and
antimetalloproteinase effects of tetracyclines are well
established. With in vitro assays, it has been shown
that the 4-dimethylamino group is required for
antibacterial activity but that removal of this moiety
does not influence MMP inhibition. In contrast,
MMP inhibition appears to require the presence of
the 11-oxy and 12-hydroxyl groups, which likely
interact with the active site zinc necessary for MMP
function.30,31,34,35 The chemical modifications rep-
resented by each CMT thereby serve to retain anti-
MMP activities and abolish antibiotic activity, and,
in some cases, they have important effects on the
bioavailability of these agents in vivo. For example,
CMT-8 (the 4-didemethylamino derivative of doxy-
cycline) has been shown to have the most favorable
pharmacologic profile of the 4 compounds tested in
this study.35
Additional concerns will need to be addressed
before tetracycline derivatives can be considered for
clinical evaluation in patients with AAA. For
instance, subcutaneous administration was chosen in
this study for its consistency, yet all the tetracycline
derivatives used here can be administered orally with
maintenance of anti-MMP activity.36,42 Future stud-
ies on AAA will therefore need to address variables
associated with gastrointestinal absorption, metabo-
lism, and excretion of orally administered tetracy-
cline derivatives. It also will be necessary to measure
serum and tissue drug concentrations to better
establish the levels required to effectively inhibit var-
ious MMPs within aneurysms in vivo. These consid-
erations may be important in the clinical application
of tetracyclines for AAA because it has been found
that low-dose doxycycline (20 mg orally twice daily)
and even cyclic regimens (alternating months) may
be as effective as traditional dose schedules in the
treatment of other conditions.36,42 Although tetra-
cycline derivatives are presently in clinical trials for
several disorders, which include periodontitis, arthri-
tis, and the suppression of metastasis in cancer, these
questions will need to be addressed in more detail
before initiating investigations on human AAA.
A second consideration is that tetracyclines are
nonspecific with respect to their inhibition of differ-
ent MMPs. It is not yet known, for example, if 92-
kD gelatinase is the predominant elastolytic MMP
responsible for elastin degradation in aortic
aneurysms, either in the elastase-induced rat model
or in human disease.20 This point has been empha-
sized by recent observations from our laboratory,
which indicate that macrophage metalloelastase
(MMP-12) may participate even more directly in
aortic elastin degradation than MMP-2, MMP-9, or
other enzymes.21 Although the specific collagenases
involved in AAA are not yet well defined, it is also
likely that MMP-mediated degradation of collagen is
at least as important as that of elastin during pro-
gressive aneurysm growth. It therefore remains pos-
sible that therapeutic strategies on the basis of MMP
inhibition could be more effective if targeted to 1 or
more individual MMP family members that might
play a particularly important role in aneurysmal
degeneration.
Third, more knowledge is needed regarding sec-
ondary mechanisms by which tetracycline derivatives
might act to suppress elastase-induced AAA.
Whereas tetracyclines have been thought to act pri-
marily as direct pharmacologic MMP inhibitors,30
there is some evidence that these agents could also
lead to a reduction in MMP gene expression.43
Moreover, tetracyclines can exert additional effects
in vivo as a consequence of their MMP-inhibiting
properties, some of which have broad consequences
relevant to the pathophysiology of aneurysmal
degeneration. For example, one effect of MMP inhi-
bition may be to prevent the metalloproteinase-
mediated degradation of serine proteinase
inhibitors, such as a 1-antiproteinase ( a 1-AP).44,45
Because a 1-AP may be important in sequestering
JOURNAL OF VASCULAR SURGERY
Volume 28, Number 6 Curci et al 1091
serine proteases (ie, neutrophil elastase) within
inflammatory tissues, local elevations in a 1-AP
would likely enhance the preservation of aortic wall
connective tissue. MMP inhibition also may affect
the production of inflammatory cytokines and other
mediators, as exemplified by the suppression of the
membrane metalloproteinase required for extracel-
lular release of tumor necrosis factor- a .46 Tetra-
cyclines therefore may inhibit the release of biologi-
cally active tumor necrosis factor- a within the
injured aortic wall, subsequently reducing inflamma-
tory cell production of MMPs. Another possibility is
suggested by the finding that both doxycycline and
CMTs inhibit cellular expression of inducible nitric
oxide synthase, an enzyme responsible for nitric
oxide production in inflammatory conditions.47
Because nitric oxide may also induce inflammatory
cell expression of MMPs, and their extracellular acti-
vation,48 tetracyclines might act through this mech-
anism to interrupt another important casacade
involved in matrix degradation. Our data suggest
that these secondary mechanisms likely occur at the
highest dose of doxycycline tested in the rat model,
60 mg/kg/day, where a reduction in extractable 92-
kD gelatinase was observed. Indeed, the combina-
tion of these various effects may make tetracyclines
even more effective in preventing connective tissue
destruction than agents specifically tailored to indi-
vidual MMPs.
Finally, it is not yet known if tetracyclines or
other MMP inhibitors will actually prevent the pro-
gressive enlargement of AAAs as they are encoun-
tered in clinical practice.1 This will be an important
concern in considering the application of these ther-
apeutic strategies to patients with small AAAs, a set-
ting where the pathophysiologic processes leading to
aneurysm development have already become well
established. It therefore will remain necessary to
show that MMP-inhibiting strategies can suppress
the growth of established AAAs with the same effi-
Fig 5. Effect of tetracyclines on matrix metalloproteinase activities extractable from elastase-
injured rat aorta. Rats were treated with tetracycline derivatives for 7 days after elastase-
induced aortic injury. Aortic tissue extracts were normalized to total protein concentration and
examined by gelatin substrate zymography. A, Gelatinase activities in extracts from rats treat-
ed with varying doses (0 to 60 mg/kg/day) of doxycycline. B, Gelatinase activities in extracts
from rats treated with doxycycline or chemically modified tetracyclines at 15 mg/kg/day. C,
Calculated relative density corresponding to 92-kD and 72-kD gelatinase activities detected in
A (percent of normal aorta). D, Calculated relative density corresponding to 92-kD and 72-
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cacy that they have on aneurysm development, in
both experimental models and eventually in clinical
trials. The present study adds to our understanding
of this process and therefore serves as a useful start-
ing point for future investigation.
We thank Drs William C. Parks and Robert P.
Mecham for helpful discussions.
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